Vertex Pharmaceuticals stock gains on higher 2026 guidance

Published on 09/19/2026 at 13:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharmaceuticals stock rose 13 percent year to date as it lifted full-year revenue guidance to USD 13.1 billion to USD 13.2 billion on September 18, 2026. Q2 2026 revenue reached USD 3.33 billion and diluted EPS was USD 4.31.

Wissenschaftler pipettiert Proben in modernem Biotech-Labor mit Automatisierungsgeräten — Vertex Pharma US92532F1003 zeigt einen Forscher im modernen Labor mit Pipette an sterilem Edelstahltisch, Illustration mit AI erstellt.

Vertex Pharmaceuticals Incorporated (US92532F1003) stock closed at USD 508.34 on September 18, 2026, down 1.55 percent, while the 52-week range on Yahoo Finance ran from USD 341.90 to USD 510.64 and market capitalization stood at USD 124.33 billion.

Higher guidance sets the tone

On September 18, 2026, Motley Fool wrote that Vertex raised full-year revenue guidance to USD 13.1 billion to USD 13.2 billion from USD 12.95 billion to USD 13.1 billion. The same report said second-quarter revenue increased 12 percent year over year to USD 3.33 billion and diluted EPS climbed 8 percent to USD 4.31.

That combination matters because the new revenue range adds up to USD 150 million at the top end versus the prior ceiling, while the quarter delivered USD 3.33 billion on the way to that target. Vertex also had USD 13.64 billion in cash, cash equivalents and marketable securities as of June 30, 2026, according to StockTitan, alongside USD 2.55 billion in first-half operating cash flow.

Valuation stays tight

Yahoo Finance showed Vertex at USD 508.34 on September 18, 2026, with average volume of 1,097,317 shares, a previous close of USD 476.15 and a day range of USD 475.87 to USD 482.89 in the same quote snapshot. MarketBeat listed a consensus target price of USD 570.83 for Vertex and a consensus rating of Moderate Buy, while JPMorgan reiterated Overweight and lifted its target from USD 515.00 to USD 560.00 on September 10, 2026.

The stock therefore traded only USD 2.30 below the 52-week high of USD 510.64 in the Yahoo Finance snapshot, and the September 10 JPMorgan note framed the setup as a target move from USD 515.00 to USD 560.00. For investors, the gap between price and target is now the number to watch most closely.

Price and range

Vertex Pharmaceuticals stock closed at USD 508.34 on September 18, 2026, in Nasdaq trading. That left the shares near the top of their USD 341.90 to USD 510.64 52-week range.